Advanced search
1 file | 2.22 MB

Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma : a cross-sectional case-control study

(2017) ONCOTARGET. 8(53). p.91593-91602
Author
Organization
Abstract
Rationale: Malignant pleural mesothelioma (MPM) is mainly caused by previous exposure to asbestos fibers and has a poor prognosis. Due to a long latency period between exposure and diagnosis, MPM incidence is expected to peak between 2020-2025. Screening of asbestos-exposed individuals is believed to improve early detection and hence, MPM management. Recent developments focus on breath analysis for screening since breath contains volatile organic compounds (VOCs) which reflect the cell’s metabolism. Objectives: The goal of this cross-sectional, case-control study is to identify VOCs in exhaled breath of MPM patients with gas chromatography-mass spectrometry (GC-MS) and to assess breath analysis to screen for MPM using an electronic nose (eNose). Methods: Breath and background samples were taken from 64 subjects: 16 healthy controls (HC), 19 asymptomatic former asbestos-exposed (AEx) individuals, 15 patients with benign asbestos-related diseases (ARD) and 14 MPM patients. Samples were analyzed with both GC-MS and eNose. Results: Using GC-MS, AEx individuals were discriminated from MPM patients with 97% accuracy, with diethyl ether, limonene, nonanal, methylcyclopentane and cyclohexane as important VOCs. This was validated by eNose analysis. MPM patients were discriminated from AEx+ARD participants by GC-MS and eNose with 94% and 74% accuracy, respectively. The sensitivity, specificity, positive and negative predictive values were 100%, 91%, 82%, 100% for GC-MS and 82%, 55%, 82%, 55% for eNose, respectively. Conclusion: This study shows accurate discrimination of patients with MPM from asymptomatic asbestos-exposed persons at risk by GC-MS and eNose analysis of exhaled VOCs and provides proof-of-principle of breath analysis for MPM screening.
Keywords
mesothelioma, breath tests, volatile organic compounds, gas chromatography-mass spectrometry, electronic nose, EXHALED BREATH, LUNG-CANCER, ASBESTOS, DIAGNOSIS, BIOMARKER

Downloads

  • 21335-304418-1-PB.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.22 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Lamote, Kevin, Paul Brinkman, Lore Vandermeersch, Matthijs Vynck, Peter J Sterk, Herman Van Langenhove, Olivier Thas, Joris Van Cleemput, Kristiaan Nackaerts, and Jan Van Meerbeeck. 2017. “Breath Analysis by Gas Chromatography-mass Spectrometry and Electronic Nose to Screen for Pleural Mesothelioma : a Cross-sectional Case-control Study.” Oncotarget 8 (53): 91593–91602.
APA
Lamote, K., Brinkman, P., Vandermeersch, L., Vynck, M., Sterk, P. J., Van Langenhove, H., Thas, O., et al. (2017). Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma : a cross-sectional case-control study. ONCOTARGET, 8(53), 91593–91602.
Vancouver
1.
Lamote K, Brinkman P, Vandermeersch L, Vynck M, Sterk PJ, Van Langenhove H, et al. Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma : a cross-sectional case-control study. ONCOTARGET. 2017;8(53):91593–602.
MLA
Lamote, Kevin et al. “Breath Analysis by Gas Chromatography-mass Spectrometry and Electronic Nose to Screen for Pleural Mesothelioma : a Cross-sectional Case-control Study.” ONCOTARGET 8.53 (2017): 91593–91602. Print.
@article{8533148,
  abstract     = {Rationale: Malignant pleural mesothelioma (MPM) is mainly caused by previous exposure to asbestos fibers and has a poor prognosis. Due to a long latency period between exposure and diagnosis, MPM incidence is expected to peak between 2020-2025. Screening of asbestos-exposed individuals is believed to improve early detection and hence, MPM management. Recent developments focus on breath analysis for screening since breath contains volatile organic compounds (VOCs) which reflect the cell{\textquoteright}s metabolism.
Objectives: The goal of this cross-sectional, case-control study is to identify VOCs in exhaled breath of MPM patients with gas chromatography-mass spectrometry (GC-MS) and to assess breath analysis to screen for MPM using an electronic nose (eNose).
Methods: Breath and background samples were taken from 64 subjects: 16 healthy controls (HC), 19 asymptomatic former asbestos-exposed (AEx) individuals, 15 patients with benign asbestos-related diseases (ARD) and 14 MPM patients. Samples were analyzed with both GC-MS and eNose.
Results: Using GC-MS, AEx individuals were discriminated from MPM patients with 97\% accuracy, with diethyl ether, limonene, nonanal, methylcyclopentane and cyclohexane as important VOCs. This was validated by eNose analysis. MPM patients were discriminated from AEx+ARD participants by GC-MS and eNose with 94\% and 74\% accuracy, respectively. The sensitivity, specificity, positive and negative predictive values were 100\%, 91\%, 82\%, 100\% for GC-MS and 82\%, 55\%, 82\%, 55\% for eNose, respectively.
Conclusion: This study shows accurate discrimination of patients with MPM from asymptomatic asbestos-exposed persons at risk by GC-MS and eNose analysis of exhaled VOCs and provides proof-of-principle of breath analysis for MPM screening.},
  author       = {Lamote, Kevin and Brinkman, Paul and Vandermeersch, Lore and Vynck, Matthijs and Sterk, Peter J and Van Langenhove, Herman and Thas, Olivier and Van Cleemput, Joris and Nackaerts, Kristiaan and Van Meerbeeck, Jan},
  issn         = {1949-2553},
  journal      = {ONCOTARGET},
  language     = {eng},
  number       = {53},
  pages        = {91593--91602},
  title        = {Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma : a cross-sectional case-control study},
  url          = {http://dx.doi.org/10.18632/oncotarget.21335},
  volume       = {8},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: